ArticlePLoS neglected tropical diseases2026
Comparative evaluation of four immunoassays for Plasmodium vivax serological detection using recombinant PvMSP1-42 antigen.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerological surveillance is a vital component in the control and elimination of Plasmodium vivax, particularly during low-transmission or elimination phases. Immunoassays are core tools for malaria serological surveillance. Among them, protein arrays, dot blot, enzyme-linked immunosorbent assay (ELISA), and Western blot are widely used, each with distinct diagnostic and operational characteristics.
methodsWe evaluated a recombinant His-tagged PvMSP1-42 protein using sera from immunized mice, P. vivax-infected patients, and healthy individuals across the platforms under standardized conditions.
resultsAll immunoassays demonstrated high reproducibility but varied in sensitivity and sample requirements. Protein arrays enabled a broad detection range (3.13-200 ng/μl) with minimal protein and antibody use, with performance further enhanced using a protein stabilizing diluent. Dot blot and Western blot exhibited similar detection thresholds (6.25-200 ng/μl), although dot blot showed improved sensitivity at low serum dilutions when using Protein Microarray Spot Diluent. ELISA achieved the highest sensitivity, detecting specific antibodies at dilutions up to 1:128,000, but plateaued beyond 50 ng/μl of antigen. Apart from the dot blot, the other methods demonstrated both sensitivity and specificity exceeding 90%, whereas dot blot sensitivity remained lower at 80%.
conclusionsProtein arrays offered a favorable balance between sensitivity, throughput capability and sample conservation. ELISA was the most effective for detecting low antibody titers. Dot blot and Western blot remained useful, depending on resource availability and experimental goals. These findings provide a practical reference for selecting appropriate immunoassay platforms for malaria serology and for developing scalable serosurveillance strategies in elimination-phase settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.